About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Texas | 12,973 Studies Near You | Clareo Health

Clinical Trials LocationsTexas

Clinical Trials in Texas

Discover 12,973 clinical trials near Texas. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 2381-2400 of 12,973 trials

Active Not Recruiting55 miles

STOP Persistent AF PAS

NCT05005949

The STOP Persistent AF Post Approval Study (PAS) is a prospective, global, multicenter, observational trial.

Persistent Atrial Fibrillation

Medtronic Cardiac Ablation Solutions400 participantsStarted Aug 2021

Hartford, Connecticut, United States • Stamford, Connecticut, United States • Clearwater, Florida, United States +14 more locations

COMPLETEDPhase 355 miles

A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)

NCT05113745

This study will evaluate the long-term efficacy and safety of AXS-12 in narcoleptic subjects with cataplexy and excessive daytime sleepiness (EDS).

NarcolepsyCataplexyExcessive Daytime Sleepiness

Axsome Therapeutics, Inc.68 participantsStarted Oct 2021

Phoenix, Arizona, United States • Boulder, Colorado, United States • Colorado Springs, Colorado, United States +22 more locations

Find Trials by Condition in Texas

Breast Cancerin Texas Lung Cancerin Texas Prostate Cancerin Texas Colorectal Cancerin Texas Melanomain Texas Leukemiain Texas Lymphomain Texas Pancreatic Cancerin Texas Ovarian Cancerin Texas Brain Cancerin Texas Diabetesin Texas

Data from ClinicalTrials.govTerms

Active Not RecruitingPhase 255 miles

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

NCT06643481

This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ALS symptoms onset). The study comprises a core double-blind (DB) 40-week treatment period followed by an open label extension (OLE).

Amyotrophic Lateral Sclerosis (ALS)

Novartis Pharmaceuticals251 participantsStarted Oct 2024

La Jolla, California, United States • Loma Linda, California, United States • Los Angeles, California, United States +89 more locations

COMPLETEDPhase 255 miles

Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease

NCT06482437

This Phase 2a study aims to evaluate the efficacy, safety and tolerability of NMD670 vs placebo administered twice a day (BID) for 21 days in ambulatory adult patients with Charcot-Marie-Tooth disease type 1 and type 2.

Charcot-Marie-Tooth Disease

NMD Pharma A/S81 participantsStarted Sep 2024

Kansas City, Kansas, United States • Boston, Massachusetts, United States • Columbia, Missouri, United States +16 more locations

COMPLETEDPhase 1/255 miles

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

NCT03363893

This is a modular, Phase I/II, multicentre study to investigate CT7001 monotherapy in advanced solid malignancies and to further investigate CT7001 as monotherapy or in combination with standard therapy in specific participant groups with Triple Negative Breast Cancer (TNBC), Castrate Resistant Prostate Cancer (CRPC) and in combination with fulvestrant for patients with hormone receptor-positive (HR+ve) / human epidermal growth factor-2 negative (HER2-ve) breast cancer.

Advanced Solid Malignancies

Carrick Therapeutics Limited124 participantsStarted Nov 2017

Tucson, Arizona, United States • Beverly Hills, California, United States • Tampa, Florida, United States +20 more locations

RECRUITINGPhase 1/255 miles

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

NCT05379985

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)+1 more

Revolution Medicines, Inc.754 participantsStarted May 2022

Orange, California, United States • Santa Monica, California, United States • Tampa, Florida, United States +13 more locations

COMPLETEDPhase 2/376 miles

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

NCT02101788

This phase II/III trial studies how well trametinib works and compares it to standard treatment with either letrozole, tamoxifen, paclitaxel, pegylated liposomal doxorubicin, or topotecan in treating patients with low-grade ovarian cancer or peritoneal cavity cancer that has come back (recurrent), become worse (progressive), or spread to other parts of the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether trametinib is more effective than standard therapy in treating patients with ovarian or peritoneal cavity cancer.

Borderline Ovarian Serous TumorMicropapillary Serous CarcinomaOvarian Serous Adenocarcinoma+3 more

National Cancer Institute (NCI)260 participantsStarted Apr 2014

Huntsville, Alabama, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +498 more locations

Active Not RecruitingPhase 276 miles

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

NCT04216290

This phase II trial studies the benefit of adding an immunotherapy drug called MEDI4736 (durvalumab) to standard chemotherapy and radiation therapy in treating bladder cancer which has spread to the lymph nodes. Drugs used in standard chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with durvalumab may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving chemotherapy and radiation therapy with the addition of durvalumab may work better in helping tumors respond to treatment compared to chemotherapy and radiation therapy alone. Patients with limited regional lymph node involvement may benefit from attempt at bladder preservation, and use of immunotherapy and systemic chemotherapy.

Bladder Urothelial CarcinomaStage III Bladder Cancer AJCC v8

National Cancer Institute (NCI)95 participantsStarted Mar 2021

Anchorage, Alaska, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +213 more locations

RECRUITING116 miles

A Study to Assess Growth in Children With Idiopathic Short Stature

NCT06309979

Study 111-903 will generate baseline growth data in children with ISS by collecting growth measurements and other variables of interest.

Idiopathic Short Stature

BioMarin Pharmaceutical300 participantsStarted Aug 2024

Phoenix, Arizona, United States • Los Angeles, California, United States • Los Angeles, California, United States +37 more locations

Active Not RecruitingPhase 2116 miles

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

NCT01878617

Historically, medulloblastoma treatment has been determined by the amount of leftover disease present after surgery, also known as clinical risk (standard vs. high risk). Recent studies have shown that medulloblastoma is made up of distinct molecular subgroups which respond differently to treatment. This suggests that clinical risk alone is not adequate to identify actual risk of recurrence. In order to address this, we will stratify medulloblastoma treatment in this phase II clinical trial based on both clinical risk (low, standard, intermediate, or high risk) and molecular subtype (WNT, SHH, or Non-WNT Non-SHH). This stratified clinical and molecular treatment approach will be used to evaluate the following: * To find out if participants with low-risk WNT tumors can be treated with a lower dose of radiation to the brain and spine, and a lower dose of the chemotherapy drug cyclophosphamide while still achieving the same survival rate as past St. Jude studies with fewer side effects. * To find out if adding targeted chemotherapy after standard chemotherapy will benefit participants with SHH positive tumors. * To find out if adding new chemotherapy agents to the standard chemotherapy will improve the outcome for intermediate and high risk Non-WNT Non-SHH tumors. * To define the cure rate for standard risk Non-WNT Non-SHH tumors treated with reduced dose cyclophosphamide and compare this to participants from the past St. Jude study. All participants on this study will have surgery to remove as much of the primary tumor as safely possible, radiation therapy, and chemotherapy. The amount of radiation therapy and type of chemotherapy received will be determined by the participant's treatment stratum. Treatment stratum assignment will be based on the tumor's molecular subgroup assignment and clinical risk. The participant will be assigned to one of three medulloblastoma subgroups determined by analysis of the tumor tissue for tumor biomarkers: * WNT (Strata W): positive for WNT biomarkers * SHH (Strata S): positive for SHH biomarkers * Non-WNT Non-SHH, Failed, or Indeterminate (Strata N): negative for WNT and SHH biomarkers or results are indeterminable Participants will then be assigned to a clinical risk group (low, standard, intermediate, or high) based on assessment of: * How much tumor is left after surgery * If the cancer has spread to other sites outside the brain \[i.e., to the spinal cord or within the fluid surrounding the spinal cord, called cerebrospinal fluid (CSF)\] * The appearance of the tumor cells under the microscope * Whether or not there are chromosomal abnormalities in the tumor, and if present, what type (also called cytogenetics analysis)

Medulloblastoma

St. Jude Children's Research Hospital660 participantsStarted Jun 2013

Palo Alto, California, United States • San Diego, California, United States • New Haven, Connecticut, United States +20 more locations

Active Not RecruitingPhase 2119 miles

A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06603077

The main purpose of this study is to evaluate the efficacy and safety of AVTX-009 compared with placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).

Hidradenitis Suppurativa

Avalo Therapeutics, Inc.250 participantsStarted Sep 2024

Scottsdale, Arizona, United States • Scottsdale, Arizona, United States • Tucson, Arizona, United States +86 more locations

COMPLETEDNA126 miles

The PEERLESS Study

NCT05111613

A prospective, multicenter, randomized controlled trial of the FlowTriever System compared to Catheter-Directed Thrombolysis (CDT) for use in the treatment of acute pulmonary embolism. The trial includes a non-randomized cohort of subjects with an absolute contraindication to thrombolysis.

Pulmonary EmbolismPulmonary Thromboembolism

Inari Medical692 participantsStarted Feb 2022

Loma Linda, California, United States • Orange, California, United States • Pasadena, California, United States +57 more locations

COMPLETEDNA126 miles

Functional Lumen Opening With Self-Forming Magnetic Anastomosis

NCT06454916

The primary objective of this trial is to investigate the safety and effectiveness of the Flexagon SFM system plus OTOLoc when used to create a small bowel anastomosis in subjects undergoing laparoscopic small bowel surgery.

Small Bowel Anastomosis

GI Windows, Inc.79 participantsStarted Oct 2024

Clovis, California, United States • Coral Gables, Florida, United States • Orlando, Florida, United States +4 more locations

TERMINATEDPhase 2/3127 miles

Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults

NCT04417257

A randomized, double-blind, placebo-controlled Phase 2/3 Study of LAU-7b against confirmed COVID-19 Disease in hospitalized patients at a higher risk of complications.

COVID-19 Disease

Laurent Pharmaceuticals Inc.351 participantsStarted Aug 2020

Chandler, Arizona, United States • Newport Beach, California, United States • Sacramento, California, United States +26 more locations

RECRUITINGPhase 2127 miles

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

NCT05975983

The purpose of this revised Phase IIa study is to demonstrate safety of INS018\_055 over 12 weeks in adults with Idiopathic Pulmonary Fibrosis (IPF).

Idiopathic Pulmonary Fibrosis (IPF)

InSilico Medicine Hong Kong Limited40 participantsStarted Feb 2024

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Los Angeles, California, United States +9 more locations

RECRUITINGPhase 1159 miles

Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

NCT06462183

Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC

Adenoid Cystic CarcinomaColorectal Cancer

Rgenta Therapeutics Inc105 participantsStarted Aug 2024

Boston, Massachusetts, United States • Ann Arbor, Michigan, United States • St Louis, Missouri, United States +7 more locations

RECRUITINGPhase 3159 miles

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

NCT04064060

A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants: * Participants receiving luspatercept on a parent protocol at the time of their transition to the rollover study, who tolerate the protocol-prescribed regimen in the parent trial and, in the opinion of the investigator, may derive clinical benefit from continuing treatment with luspatercept * Participants in the follow-up phase previously treated with luspatercept or placebo in the parent protocol will continue into long-term post-treatment follow-up in the rollover study until the follow-up commitments are met * The study design is divided into the Transition Phase, Treatment Phase and Follow-up Phase. Participants will enter transition phase and depending on their background will enter either the treatment phase or the Long-term Post-treatment Follow-up (LTPTFU) phase * Transition Phase is defined as one Enrollment visit * Treatment Phase: For participants in luspatercept treatment the dose and schedule of luspatercept in this study will be the same as the last dose and schedule in the parent luspatercept study. This does not apply to participants that are in long-term follow-up from the parent protocol * Follow-up Phase includes: \- 42 Day Safety Follow-up Visit * During the Safety Follow up, the participants will be followed for 42 days after the last dose of luspatercept, for the assessment of safety-related parameters and adverse event (AE) reporting \- Long-term Post-treatment Follow-up (LTPTFU) Phase * Participants will be followed for overall survival every 6 months for at least 5 years from first dose of luspatercept in the parent protocol, or 3 years of post-treatment from last dose, whichever occurs later, or until death, withdrawal of consent, study termination, or until a subject is lost to follow-up. Participants will also be monitored for progression to AML or any malignancies/pre-malignancies. New anticancer or disease related therapies should be collected at the same time schedule Participants transitioning from a parent luspatercept study in post-treatment follow-up (safety or LTPTFU) will continue from the same equivalent point in this rollover study. The ACE-536-LTFU-001 rollover study will be terminated, and relevant participants will discontinue from the study when all participants fulfill 5 years on the study, including treatment and follow-up.

Myelodysplastic Syndromes (MDS)Beta-thalassemiaMyeloproliferative Neoplasm(MPN)-Associated Myelofibrosis

Celgene665 participantsStarted Aug 2019

Los Angeles, California, United States • Oakland, California, United States • Stanford, California, United States +140 more locations

COMPLETEDPhase 2305 miles

A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial

NCT04876391

This study is open to adults with hidradenitis suppurativa who took part in a previous clinical study of a medicine called spesolimab. Participants who completed treatment can join this study. The purpose of this study is to find out how safe spesolimab is and whether it helps people with hidradenitis suppurativa in the long-term. Participants are in this study for about 2 years and 4 months. For 2 years, participants visit the study site every 2 weeks to get spesolimab injections under the skin. At study visits, doctors check the severity of participants' hidradenitis suppurativa and collect information on any health problems of the participants.

Hidradenitis Suppurativa

Boehringer Ingelheim45 participantsStarted Aug 2021

Los Angeles, California, United States • Indianapolis, Indiana, United States • Rochester, Minnesota, United States +23 more locations

TERMINATEDPhase 2854 miles

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

NCT03979508

This phase II trial studies how well abemaciclib works in treating patients with triple negative breast cancer that can be removed by surgery (resectable) and does not respond to treatment with chemotherapy alone, or in combination with pembrolizumab. Abemaciclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+15 more

Mayo Clinic26 participantsStarted Jan 2020

Scottsdale, Arizona, United States • Jacksonville, Florida, United States • Rochester, Minnesota, United States

COMPLETEDPhase 1863 miles

A Trial Evaluating TG4050 in Ovarian Carcinoma.

NCT03839524

This is a multicenter, open-label, single arm phase I study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with ovarian, fallopian or peritoneal serous carcinoma.

Ovarian CarcinomaFallopian Tube CancerPeritoneal Carcinoma

Transgene64 participantsStarted Dec 2019

Phoenix, Arizona, United States • Jacksonville, Florida, United States • Rochester, Minnesota, United States +3 more locations

PreviousPage 120 of 649Next

Heart Diseasein Texas